Advertisement

Annals of Nuclear Medicine

, Volume 33, Issue 2, pp 119–127 | Cite as

Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies

  • Akira Joraku
  • Kentaro Hatano
  • Koji Kawai
  • Shuya Kandori
  • Takahiro Kojima
  • Nobuyoshi Fukumitsu
  • Tomonori Isobe
  • Yutaro Mori
  • Muneyuki Sakata
  • Tadashi Hara
  • Katsuhiro Nasu
  • Manabu Minami
  • Yuichi Iizumi
  • Hiroyuki NishiyamaEmail author
Original Article

Abstract

Objective

We conducted the present phase I/IIa positron emission tomography (PET) imaging study with 89Zr conjugated with desferroxamine-IAB2M (89Zr-Df-IAB2M), an anti-prostate-specific membrane-antigen minibody, to assess its safety and feasibility in patients with urological cancer.

Methods

89Zr-Df-IAB2M was synthetized by IBA Molecular (Somerset, NJ, USA) and transported by air to Tsukuba Molecular Imaging Center (Tsukuba, Ibaraki, Japan).17 patients received 74 MBq (2 mCi) of 89Zr-Df-IAB2M at total mass doses of 10 mg. Whole-body and plasma clearance, normal-organ and lesion uptake, and radiation absorbed dose were estimated. We also preliminarily tested the performance of 89Zr-immuno-PET imaging for 13 patients with prostate cancer and 4 patients with other urological cancer.

Results

The administration of 89Zr-Df-IAB2M was well-tolerated, and no infusion-related reactions were observed in any patient. No adverse events were noted in the laboratory parameters, vital signs, or other parameters. The plasma clearance was biphasic, with an initial rapid phase (t 1/2 fast: 10.1 ± 3.4 h) followed by a slow phase (t 1/2 slow: 49.0 ± 22.7 h). The half-life of radioactivity in the whole body (WB t1/2) was 237 ± 9 h. The highest absorbed radiation dose was 1.67 mGy/MBq, observed in the liver and kidney. The effective dose was 0.68 ± 0.08 mSv/MBq. The radiation dose rate at 0.5 m distance from the patient was 8.67 µSv/h on day 1, and decreased to 2.26 µSv/h at 5 days after injection. Both bone and lymph node metastases were detected with 89Zr-Df-IAB2M by 24 or 48 h imaging.

Conclusions

Administration of 89Zr-Df-IAB2M was well-tolerated and safe in terms of adverse events and radiation exposure and protection. 89Zr-Df-IAB2M is feasible for usage by long-distance transportation. Further studies are warranted for analysis of its use for tumor lesion detection (UMIN000015356).

Keywords

Prostate-specific membrane antigen PET 89Zirconium-labeled tracer Urological cancer Minibody Clinical trial 

Notes

Acknowledgements

We would like to offer special thanks to Professor Motohiro Sato, who is no longer with us, for his great contribution to this work. We wish to thank the members of the Tsukuba Clinical Research and Development Organization (T-CReDO) for their critical advice in conducting the study and data management during the study period. Members of Tsukuba Molecular Imaging Center also deserve credit for carrying out PET imaging.

Compliance with ethical standards

Conflict of interest

ImaginAb (Los Angeles, CA, USA) covered the manufacturing and shipment costs of 89Zr-Df-IAB2M. Tsukuba University Hospital supported the administration cost of the patients.

References

  1. 1.
    Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729–39.CrossRefGoogle Scholar
  2. 2.
    Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 1):10–8.CrossRefGoogle Scholar
  3. 3.
    Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.Google Scholar
  4. 4.
    Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68.CrossRefGoogle Scholar
  5. 5.
    Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.CrossRefGoogle Scholar
  6. 6.
    Grant CL, Caromile LA, Durrani K, Rahman MM, Claffey KP, Fong GH, et al. Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS One. 2012;7:e41285.CrossRefGoogle Scholar
  7. 7.
    Olafsen T, Sirk SJ, Olma S, Shen CK-F, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumor Biol. 2012;33:669–77.CrossRefGoogle Scholar
  8. 8.
    Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE. Folate hydrolaseã (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol. 2011;14:1521–9.CrossRefGoogle Scholar
  9. 9.
    Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884–92.CrossRefGoogle Scholar
  10. 10.
    Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2–5.CrossRefGoogle Scholar
  11. 11.
    Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014;65:139–47.CrossRefGoogle Scholar
  12. 12.
    Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191–7.CrossRefGoogle Scholar
  13. 13.
    Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with 89Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57:1858–64.CrossRefGoogle Scholar
  14. 14.
    Jauw YWS, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, et al. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front Pharmacol. 2016;7:131.CrossRefGoogle Scholar
  15. 15.
    Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Nucl Med. 2005;46:1023–7.Google Scholar
  16. 16.
    1990 Recommendations of the International Commission on Radiological Protection (1991) ICRP Publication 60. Ann ICRP 21:1–201.CrossRefGoogle Scholar
  17. 17.
    Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007;37:316–31.CrossRefGoogle Scholar
  18. 18.
    Matsuda M, Ishikawa E, Yamamoto T, Hatano K, Joraku A, Iizumi Y, et al. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. J Neuro-Oncol. 2018;138:581–9.CrossRefGoogle Scholar
  19. 19.
    Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of 18F- and 68 Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58:947–52.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2018

Authors and Affiliations

  • Akira Joraku
    • 1
  • Kentaro Hatano
    • 2
  • Koji Kawai
    • 1
  • Shuya Kandori
    • 1
  • Takahiro Kojima
    • 1
  • Nobuyoshi Fukumitsu
    • 3
  • Tomonori Isobe
    • 4
  • Yutaro Mori
    • 4
  • Muneyuki Sakata
    • 5
  • Tadashi Hara
    • 6
  • Katsuhiro Nasu
    • 6
  • Manabu Minami
    • 6
  • Yuichi Iizumi
    • 7
  • Hiroyuki Nishiyama
    • 1
    Email author
  1. 1.Department of Urology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  2. 2.Department of Applied Molecular Imaging, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  3. 3.Department of Radiation OncologyUniversity of TsukubaTsukubaJapan
  4. 4.Department of Medical PhysicsUniversity of TsukubaTsukubaJapan
  5. 5.Research Team for NeuroimagingTokyo Metropolitan Institute of GerontologyTokyoJapan
  6. 6.Department of Diagnostic and Interventional RadiologyUniversity of TsukubaTsukubaJapan
  7. 7.Tsukuba Clinical Research and Development OrganizationUniversity of TsukubaTsukubaJapan

Personalised recommendations